Agilent (California, USA) and Sera Prognostics (Utah, USA) have formed a strategic partnership to develop proteomic assays for the prediction of pregnancy complications. Sera Prognostics is a private biotechnology company that develops diagnostic tests for these risks.

"By providing pivotal information to physicians, Sera's preterm birth predictor is designed to address an unmet medical need for a reliable, early risk assessment that has the potential to help significantly improve the health of mothers and newborns, while materially reducing the costs of care," commented Gregory C. Critchfield, chairman and chief executive officer of Sera Prognostics. "Our partnership with Agilent provides Sera with access to advanced and innovative technologies designed to deliver on the promise of personalized medicine."

Through the partnership with Agilent, Sera Prognostics has purchased a number of liquid chromatography instruments. Furthermore, Sera Prognostics is adapting sample preparation technology from Agilent to meet the demands of high-volume testing.

"Agilent and Sera Prognostics share the vision of applying the power of advanced proteomic technologies to address meaningful medical challenges," said Yvonne Linney, vice president and general manager of Agilent's Life Science Solutions Division.

For more information please visit: